Atezolizumab Regimen Fails to Extend PFS in Newly Diagnosed Ovarian Cancer
May 24, 2021 3:00 pmBy Jennifer Southall
The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study inĀ Journal of Clinical Oncology… Read more